Alpha 2.0
Login Register
» Authors » Antonios Valachis

Antonios Valachis

Explore the profile of Antonios Valachis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 363
Followers 0
Related Specialties
Oncology
General Medicine
Infectious Diseases
Top 10 Co-Authors
Evangelos Digkas
George Samonis
Gustav J Ullenhag
Ioannis Zerdes
Anthoula Koliadi
Andreas Karakatsanis
Theodoros Foukakis
Diamantis P Kofteridis
Alexios Matikas
Ali Inan El-Naggar
Published In
Breast Cancer Res Treat
Cancers (Basel)
Front Oncol
Acta Oncol
Br J Surg
Affiliations
Soon will be listed here.
Recent Articles
1.
Short-term mortality in older (≥70 years) patients with early breast cancer treated with neo-/adjuvant chemotherapy: A Swedish nationwide retrospective population-based study
Lundgren C, Engvall K, Fredriksson I, Valachis A
J Geriatr Oncol . 2025 Mar; 16(3):102220. PMID: 40086025
Introduction: There are substantial differences in the utilization of chemotherapy between younger and older patients, mainly due to the higher risk for adverse events among older patients. Short-term mortality after...
2.
Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis
Papakonstantinou A, Villacampa G, Navarro V, Oliveira M, Valachis A, Pascual T, et al.
EClinicalMedicine . 2025 Mar; 81:103116. PMID: 40034565
Background: Multiple trials have evaluated escalation strategies of endocrine therapy for early breast cancer, including ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients and extended endocrine therapy....
3.
Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
Kastora S, Pantiora E, Hong Y, Veeramani M, Azim Jr H, Chakrabarti R, et al.
Cancer Treat Rev . 2025 Jan; 133:102880. PMID: 39854791
Importance: Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors (AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These agents are associated with menopausal symptoms, adversely...
4.
Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation
Zerdes I, Filis P, Fountoukidis G, El-Naggar A, Kalofonou F, DAlessio A, et al.
J Natl Cancer Inst . 2025 Jan; PMID: 39842854
Background: Although precision oncology has rapidly been developed in recent years, its real-world impact and challenges in healthcare implementation remain underexplored. Through a meta-analysis of real-world evidence (RWE), we aimed...
5.
Genomic characterization and molecular predictive biomarkers for chemotherapy in patients with metastatic triple-negative breast cancer treated in a real-world setting
Olsson E, Lindman H, Digkas E, Thurfjell V, Ali H, Kruger U, et al.
Breast . 2025 Jan; 79:103874. PMID: 39778370
Purpose: We aimed to characterize genomic alterations with potential prognostic or predictive significance in patients with metastatic triple-negative breast cancer (mTNBC) treated with chemotherapy in a real-world setting. Patients And...
6.
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost
Staby Olsen J, Valachis A, PhLic L, Johansson B
Brachytherapy . 2024 Nov; 24(1):45-53. PMID: 39578204
Introduction: Treating localized high-risk prostate cancer with a combination of external beam radiation therapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) is a common approach. Moderately hypofractionated EBRT and a single HDR-BT...
7.
Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Ladjevardi C, Skribek M, Koliadi A, Ryden V, El-Naggar A, Digkas E, et al.
Cancer Immunol Immunother . 2024 Nov; 74(1):14. PMID: 39508883
Immunotherapy with PD-1 or PD-L1 inhibitors has become an essential treatment strategy for a growing number of malignancies. These treatments have a risk for immune-related adverse events (IRAEs). Pooled analyses...
8.
Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
Ladjevardi C, Koliadi A, Ryden V, El-Naggar A, Digkas E, Valachis A, et al.
Front Oncol . 2024 Jul; 14:1399171. PMID: 38988708
Introduction: Checkpoint inhibitors (CPI) are widely used in cancer treatment with a potential of causing immune-related adverse events (IRAEs). Several studies have reported a positive correlation between development of IRAEs...
9.
Clinical trials in older patients with cancer - typical challenges, possible solutions, and a paradigm of study design in breast cancer
Karihtala P, Schiza A, Fountzilas E, Geisler J, Meattini I, Risi E, et al.
Acta Oncol . 2024 Jun; 63:441-447. PMID: 38881342
Background And Purpose: While the prevalence of older breast cancer patients is rapidly increasing, these patients are greatly underrepresented in clinical trials. We discuss barriers to recruitment of older patients...
10.
The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
Ryden V, El-Naggar A, Koliadi A, Ladjevardi C, Digkas E, Valachis A, et al.
Pigment Cell Melanoma Res . 2023 Dec; 37(3):352-362. PMID: 38158376
Dacarbazine (DTIC) and its oral counterpart temozolomide (TMZ) have been the most used agents in advanced malignant melanoma (MM) patients and they are still used routinely. The preferred first line...